A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on May 08, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Lymphoma, Non-Hodgkin; HIV Infections
Intervention: Zidovudine (Drug)
Phase: N/A
Status: Completed
Sponsored by: Glaxo Wellcome
Summary
To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.
Clinical Details
Official title:
A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant
Study design: Interventional, Treatment, Dose Comparison
Eligibility
Minimum age: 12 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Exclusion Criteria
Co-existing Condition:
Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
Concurrent Medication:
Excluded:
- Other anti-retroviral agents.
Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
Patients must be:
- HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.
- At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).
- Also patient must fall into one of the following categories:
- Have an HIV seronegative identical twin to serve as a bone marrow donor.
- Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.
- Be a good risk candidate for bone marrow transplant.
Locations and Contacts
Johns Hopkins Hemapheresis Treatment Ctr, Baltimore, Maryland 21205, United States
Additional Information
Last updated: June 23, 2005
|
